Drug Trial Radar · NCT07502222
A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
168
Planned (sponsor's estimate)
Start
Apr 7, 2026
Primary completion
Nov 2027
Study completion Jan 10, 2028
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Mar 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of patients with moderate-to-severe atopic dermatitis.
Conditions
- Moderate-to-Severe Atopic Dermatitis
Interventions
AK139 and placeboBiological
AK139 plus placebo regimen 1-subcutaneous injection.
AK139Biological
AK139 regimen 2-subcutaneous injection.
AK139 and placeboBiological
AK139 plus placebo regimen 3-subcutaneous injection.
AK139Biological
AK139 regimen 4-subcutaneous injection.
AK139 and placeboBiological
AK139 plus placebo regimen 5-subcutaneous injection.
AK139 and placeboBiological
AK139 plus placebo regimen 6-subcutaneous injection.
PlaceboBiological
Placebo-subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity grading of Adverse Events (AE)(applicable to Part 1)Time frame: Up to Week 16 (applicable to the Q4W dosing group); Up to Week 8 (applicable to the Q2W dosing group).
- Percentage of patients who achieved Eczema Area and Severity Index (EASI)-75 (applicable to Part 2)Time frame: at week 16
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.